Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Businessman walking up on stairs to the door of opportunity for career development or business decision for new challenge, success and achievement concept, 3d rendering

Opinion

Cell and Gene Therapy Will Transform Lives—If We Let It

Mixed headlines have plagued the cell and gene therapy space of late. We believe that a renewed case of optimism is not only warranted but essential if these therapies are to reach their full potential.

November 24, 2025

8 min read

Tim Hunt

FDA

FDA Reversals Send UniQure, Biohaven, Capricor, More Into a ‘Tailspin’

Since July, several biotechs have been forced to pivot as previous agreements with the FDA around evidence required for approval were reversed, a phenomenon that, according to experts, could portend a more restrictive regulator.

November 24, 2025

7 min read

Heather McKenzie

Rare diseases

FDA Probing Patient Death Linked to Takeda’s Enzyme Replacement Therapy

The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the protein the therapy replaces.

November 21, 2025

1 min read

Dan Samorodnitsky

Vector Illustration Of Athletes Running On Race Track

Regulatory

6 Biotechs With a Shot at the FDA’s Platform Technology Designation

After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the regulator’s radar.

November 21, 2025

9 min read

Tristan Manalac

Isometric businessman tightrope walker is on the rope. Teetering on the cable. Business challenge and risk concept. Simple minimal design. Trendy style graphic. Flat vector illustration.

Multiple sclerosis

J&J, Contineum Fail ‘Risky’ Mid-Stage Multiple Sclerosis Trial

While expressing disappointment, William Blair analysts were unsurprised by the Phase II failure, having assigned the VISTA study a high level of risk given the “mixed” performance of a similar drug in a prior multiple sclerosis study.

November 21, 2025

2 min read

Tristan Manalac

Poznan, Poland - 5 October 2024: GSK -Glaxosmithkline headquarters office building in Poznan.

Legal

UPDATE: GSK’s Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues

After GSK subsidiary Tesaro filed a lawsuit Thursday claiming that AnaptysBio breached “certain requirements” under their 2014 license agreement involving GSK’s Jemperli, Anaptys responded Friday morning.

November 21, 2025

3 min read

Tristan Manalac

Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.

Pipeline

Moderna Cans 3 mRNA Vaccines, Secures $1.5B Loan in Quest for 10% Growth

Amid an aggressive savings push, Moderna has cut three assets and taken on a loan to increase “flexibility.”

November 21, 2025

2 min read

Tristan Manalac

Four miniature figurines of men in casual and formal attire stand around a large stopwatch showing zero, symbolizing time management or competition.

Regulatory

FDA Breakthrough Designations Lead to Priority Reviews, Report Finds

A new analysis from Jefferies shows that drugs receiving breakthrough designations sail through the regulatory process more quickly, on top of frequently winning approval.

November 20, 2025

1 min read

Dan Samorodnitsky